8-K: Baxter International Reports Strong Q4 and Full-Year 2024 Results, Exceeding Guidance

Baxter International Inc. announces positive fourth-quarter and full-year 2024 results, surpassing previous guidance, and completes the sale of its Kidney Care business.

Summary

• Baxter International Inc. reported its fourth-quarter and full-year results for 2024.
• Fourth-quarter sales from continuing operations reached $2.75 billion, a 1% increase on a reported basis and a 2% increase on a constant currency basis, exceeding the company's previous guidance.
• The U.S. GAAP diluted loss per share (EPS) from continuing operations was ($0.95) for the fourth quarter, while adjusted diluted EPS from continuing operations was $0.58, also exceeding guidance.
• Full-year sales from continuing operations totaled $10.64 billion, a 3% increase on both a reported and constant currency basis, exceeding previous guidance.
• The full-year U.S. GAAP diluted loss per share from continuing operations was ($0.64), while adjusted diluted EPS from continuing operations was $1.89, exceeding guidance.
• The sale of the Kidney Care business to Carlyle was completed on January 31, 2025, for approximately $3.4 billion of net after-tax proceeds, exceeding previous expectations of $3.15 to $3.25 billion.
• Baxter is allocating the net after-tax proceeds from the Kidney Care sale towards debt repayment, aiming for a net leverage target of approximately 3.0x by the end of 2025.
• For full-year 2025, Baxter expects sales growth from continuing operations of 5% to 6% on a reported basis and adjusted earnings from continuing operations of $2.45 to $2.55 per diluted share.
• For the first quarter of 2025, the company expects sales growth from continuing operations of 3% to 4% on a reported basis and adjusted earnings from continuing operations of $0.47 to $0.50 per diluted share.

Sentiment

Score: 7

Explanation: The sentiment is positive due to exceeding guidance and completing a strategic divestiture, but tempered by GAAP losses and the impact of Hurricane Helene.

Positives

• Baxter exceeded its previously issued guidance for fourth-quarter and full-year sales and adjusted diluted EPS from continuing operations.
• The sale of the Kidney Care business was completed for a higher amount than initially expected.
• Baxter is strategically using the proceeds from the Kidney Care sale to reduce debt.
• The company is projecting sales growth and adjusted earnings for 2025.
• The company's Medical Products & Therapies and Pharmaceuticals segments showed strong performance in the fourth quarter.

Negatives

• Baxter reported a U.S. GAAP diluted loss per share from continuing operations of ($0.95) for the fourth quarter and ($0.64) for the full year.
• Healthcare Systems & Technologies sales declined by low single digits on a reported and constant currency basis.
• The company incurred special items totaling $908 million after-tax in the fourth quarter and $2.13 billion after-tax for the full year, impacting U.S. GAAP results.
• Baxter's North Cove, North Carolina, manufacturing site was significantly impacted by flooding related to Hurricane Helene, resulting in a temporary production shutdown.

Risks

• The company's ability to achieve the intended benefits of its recent strategic actions, including the sale of the Kidney Care business, and cost-saving initiatives.
• The company's ability to successfully integrate acquisitions, including the acquisition of Hill-Rom Holdings, Inc.
• The impact of global economic conditions, including changes in taxation, tariffs, trade policies and treaties, sanctions, embargos, export control restrictions, inflation levels and interest rates, financial market volatility, banking crises, the potential for a recession, the war in Ukraine, the conflict in the Middle East, other geopolitical events and the potential for escalation of these conflicts, the related economic sanctions being imposed globally in response to the conflicts and potential trade wars, global public health crises, pandemics and epidemics, or the anticipation of any of the foregoing, on the company's operations and on the company's employees, customers, suppliers, and foreign governments in countries in which the company operates.
• Failure to accurately forecast or achieve the company's shortand long-term financial performance and goals, market and category growth rates, and related impacts on the company's liquidity.
• The company's ability to execute on its capital allocation plans, including the company's debt repayment plans, the timing and amount of any dividends, share repurchases and divestiture proceeds.
• Downgrades to the company's credit ratings or ratings outlooks, or withdrawals by rating agencies from rating the company and its indebtedness, and the impact on the company's funding costs and liquidity.
• Fluctuations in foreign exchange and interest rates.
• The impact of any goodwill, intangible asset, or other long-lived asset impairments on the company's operating results.
• The company's ability to finance and develop new products or services, or enhancements thereto, on commercially acceptable terms or at all.
• Product development risks, including satisfactory clinical performance and obtaining and maintaining required regulatory approvals (including as a result of evolving regulatory requirements or the withdrawal or resubmission of any pending applications), the ability to manufacture at appropriate scale, and the general unpredictability associated with the product development cycle.
• Demand and market acceptance risks for, and competitive pressures related to, new and existing products and services, challenges with the company's ability to accurately predict changing customer preferences and future expenditures and inventory levels, and challenges with the company's ability to monetize new and existing products and services (and to sustain any related price increases), the impact of those products and services on quality and patient safety concerns, and the need for ongoing training and support for the company's products and services.
• The impact of competitive products and pricing, including generic competition, drug reimportation, and disruptive technologies.
• Regulatory agency inspections, product quality or patient safety issues leading to product recalls, withdrawals, labeling changes, launch delays, warning letters, import bans, denial of import certifications, sanctions, seizures, litigation, or declining sales, including the focus on evaluating product portfolios for the potential presence or formation of nitrosamines.
• Future actions of, or failures to act or delays in acting by FDA, the European Medicines Agency, or any other regulatory body or government authority (including the U.S. Securities and Exchange Commission, Department of Justice, or the Attorney General of any state) that could delay, limit or suspend product development, manufacturing or sale, or result in seizures, recalls, injunctions, monetary sanctions or criminal or civil liabilities.
• Failures with respect to the company's quality, compliance or ethics programs.
• Loss of key employees, including senior management, the occurrence of labor disruptions (including as a result of labor disagreements under bargaining agreements or national trade union agreements or disputes with works councils) or the inability to attract, develop, retain and engage employees.
• Inability to create additional production capacity in a timely manner or the occurrence of other manufacturing, sterilization, or supply difficulties, including as a result of natural disaster (such as Hurricane Helene), war, terrorism, global public health crises and epidemics/pandemics, regulatory actions or otherwise.
• Future actions of third parties, including third-party payors and the company's customers and distributors (including GPOs and IDNs).
• The continuity, availability, and pricing of acceptable raw materials and component parts, the company's ability to pass some or all of these costs to the company's customers through price increases or otherwise, and the related continuity of the company's manufacturing and distribution and those of the company's suppliers.
• Breaches, including by cyber-attack, data leakage, unauthorized access or theft, or failures of or vulnerabilities in, the company's information technology systems or products.
• The company's ability to effectively develop, integrate or deploy artificial intelligence, machine learning and other emerging technologies into the company's products, services and operations in a manner that is compliant with existing and emerging regulations.
• The impact of physical effects of climate change, severe storms (including Hurricane Helene) and storm-related events, including the company's ability to resume production at its North Cove facility to pre-hurricane levels and to complete the remediation.
• Changes to legislation and regulation and other governmental pressures in the United States and globally, including the cost of compliance and potential penalties for purported noncompliance thereof, including new or amended laws, rules and regulations as well as the impact of healthcare reform and its implementation, suspension, repeal, replacement, amendment, modification and other similar actions undertaken by the United States or foreign governments, including with respect to pricing, reimbursement, taxation and rebate policies.
• The company's ability to meet evolving and varied corporate responsibility expectations of the company's stakeholders, including compliance with new and emerging sustainability regulations.
• Global regulatory, trade, and tax policies, including with respect to climate change and other sustainability matters.
• The ability to protect or enforce the company's patents or other proprietary rights (including trademarks, copyrights, trade secrets, and know-how) or where the patents of third parties prevent or restrict the company's manufacture, sale or use of affected products or technology.
• Any changes in law concerning the taxation of income (whether with respect to current or future tax reform).
• Actions by tax authorities in connection with ongoing tax audits.
• The outcome of pending or future litigation.
• Other risks discussed in Baxter's most recent filings on Form 10-K and Form 10-Q and other SEC filings, all of which are available on Baxter's website.

Future Outlook

Baxter expects full-year 2025 sales growth from continuing operations of 5% to 6% on a reported basis and adjusted earnings from continuing operations of $2.45 to $2.55 per diluted share; for first-quarter 2025, the company expects sales growth from continuing operations of 3% to 4% on a reported basis and adjusted earnings from continuing operations of $0.47 to $0.50 per diluted share.

Management Comments

• 'Our 2024 performance and related strategic milestones reflect Baxters growing momentum in our pursuit of enhanced value for patients, healthcare providers, customers and shareholders,' said Brent Shafer, chair and interim chief executive officer.
• 'The recently completed Kidney Care sale is a major inflection point in our journey to transform Baxter and create value for our stakeholders,' said Joel Grade, executive vice president and chief financial officer.
• Mr. Grade also stated that net after-tax proceeds from the transaction are being allocated toward debt repayment, aligned with the objective of reaching a net leverage target of approximately 3.0x by the end of 2025.
• Mr. Grade also stated that the goal is to harness the opportunities created by the newly streamlined profile and strategic trajectory with a focus on improving cash flow generation and investing in the businesses to accelerate growth.

Industry Context

Baxter's strategic moves, including the sale of its Kidney Care business, reflect a broader trend in the healthcare industry towards streamlining operations and focusing on core competencies to drive growth and innovation. The company's emphasis on medically essential products and customer-inspired innovation aligns with the industry's increasing focus on value-based healthcare and patient-centric solutions.

Comparison to Industry Standards

• Baxter's performance can be compared to other large medical technology companies such as Medtronic, Johnson & Johnson (MedTech segment), and Abbott.
• Medtronic, for example, has also been focusing on strategic portfolio management, including acquisitions and divestitures, to optimize its business and drive growth.
• Johnson & Johnson's MedTech segment has been investing in innovative technologies and solutions to address unmet patient needs.
• Abbott has been focused on expanding its presence in key growth markets and investing in research and development to drive innovation.
• Baxter's focus on debt repayment and achieving a net leverage target of approximately 3.0x is a common financial strategy among large medtech companies to maintain financial flexibility and invest in future growth opportunities.
• The company's projected sales growth and adjusted earnings for 2025 are also in line with industry expectations for large medtech companies, which are expected to benefit from an aging population, increasing prevalence of chronic diseases, and technological advancements.

Management Changes

Stakeholder Impact

• Shareholders are expected to benefit from the company's strategic transformation and focus on profitable growth.
• Patients will benefit from Baxter's continued innovation and commitment to providing medically essential products.
• Employees may experience changes due to the company's restructuring and cost-saving initiatives.
• Healthcare providers and customers will continue to rely on Baxter's portfolio of diagnostic, critical care, nutrition, hospital, and surgical products.

Next Steps

• Baxter will continue to execute its strategic priorities, including investing in its businesses to accelerate growth.
• The company will focus on improving its cash flow generation.
• Baxter will continue its search for a permanent CEO.
• The company will publish its 2024 Corporate Responsibility report later this year.

Key Dates

Keywords

Baxter, Financial Results, Kidney Care, Sales Growth, Earnings Per Share, Medtech, Healthcare, Divestiture, Guidance